Deep molecular response in patients with chronic phase chronic myeloid leukemia treated with the plasminogen activator inhibitor‐1 inhibitor TM5614 combined with a tyrosine kinase inhibitor
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.5292
Abstract: We recently showed that pharmacological inhibition of plasminogen activator inhibitor‐1 (PAI‐1) activity, based on TM5614, increases cell motility and induces the detachment of hematopoietic stem cells from their niches. In this TM5614 phase II clinical… read more here.
Keywords: deep molecular; activator inhibitor; plasminogen activator; inhibitor ... See more keywords
Results of the European survey on the assessment of deep molecular response in chronic phase CML patients during tyrosine kinase inhibitor therapy (EUREKA registry)
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Cancer Research and Clinical Oncology"
DOI: 10.1007/s00432-019-02910-6
Abstract: PurposeThe advent of tyrosine kinase inhibitor (TKI) therapies has revolutionized the treatment of chronic myeloid leukemia (CML). The European LeukemiaNet (ELN) recommends quantification of BCR–ABL1 transcripts by real-time quantitative PCR every 3 months during TKI treatment.… read more here.
Keywords: response; molecular response; deep molecular; kinase inhibitor ... See more keywords
Dasatinib cessation after deep molecular response exceeding 2 years and natural killer cell transition during dasatinib consolidation
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Science"
DOI: 10.1111/cas.13430
Abstract: Tyrosine kinase inhibitors (TKI) improve the prognosis of patients with chronic myelogenous leukemia (CML) by inducing substantial deep molecular responses (DMR); some patients have successfully discontinued TKI therapy after maintaining DMR for ≥1 year. In… read more here.
Keywords: consolidation; dasatinib consolidation; deep molecular; natural killer ... See more keywords
Deep molecular response to gilteritinib to improve survival in FLT3 mutation-positive relapsed/refractory acute myeloid leukemia.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.7003
Abstract: 7003Background: Gilteritinib, a highly selective FLT3/AXL inhibitor, has displayed antileukemic activity in FLT3 mutation-positive (FLT3mut+) relapsed/refractory (R/R) AML in the CHRYSALIS Phase I/... read more here.
Keywords: relapsed refractory; gilteritinib; mutation positive; deep molecular ... See more keywords
Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan
Sign Up to like & getrecommendations! Published in 2018 at "Haematologica"
DOI: 10.3324/haematol.2018.194894
Abstract: The purpose of this trial was to evaluate the efficacy of 2-year consolidation therapy with nilotinib, at a dose of 300 mg twice daily, for achieving treatment-free remission in chronic myeloid leukemia patients with a… read more here.
Keywords: treatment free; molecular response; deep molecular; treatment ... See more keywords
Incidences of Deep Molecular Responses and Treatment-Free Remission in de Novo CP-CML Patients
Sign Up to like & getrecommendations! Published in 2020 at "Cancers"
DOI: 10.3390/cancers12092521
Abstract: Simple Summary Tyrosine kinase inhibitors (TKI) can be safely discontinued in chronic myeloid leukemia patients. Achieving a sustained deep molecular response (DMR) before stop is recommended. Currently, the proportion of patients who achieve a sustained… read more here.
Keywords: cml patients; sustained dmr; deep molecular; dmr ... See more keywords